...
首页> 外文期刊>Therapeutic Drug Monitoring >The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in chinese adult liver-transplant patients
【24h】

The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in chinese adult liver-transplant patients

机译:人群药代动力学分析显示磺脲类药物对他克莫司表观清除率的影响在中国成年肝移植患者中

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: The aims of this study were to determine the population pharmacokinetics of tacrolimus in Chinese adult liver-transplant recipients and to identify factors that may account for this variability. Methods: Tacrolimus dose and blood concentrations, along with clinical data, were collected retrospectively from 262 liver-transplant recipients. Data were analyzed using a nonlinear mixed-effects modeling method. A 1-compartment model with first-order absorption and elimination was selected as the base model. The influence of the following parameters were explored: (1) demographic characteristics, (2) biochemical and hematological laboratory test results, (3) surgery parameters, and (4) commonly used comedications. Results: The typical values (interindividual variability percent coefficient of variation) for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 20.9 L h -1 (23.8%) and 808 l (70.4%), respectively. The residual variability was 33.6%. Finally, the 4 covariates that showed a strong correlation with CL/F in this study were daily dose, hematocrit, total plasma protein, and the coadministration of sulfonylureas. CL/F was reduced significantly with sulfonylureas cotherapy, higher hematocrit levels, and elevated total protein. Moreover, CL/F increased nonlinearly with larger daily doses of tacrolimus. Conclusions: Concurrent therapy with sulfonylureas influenced tacrolimus CL/F in liver transplantation patients. These results and model will help clinicians to optimize tacrolimus regimens in Chinese liver transplantation patients.
机译:目的:本研究的目的是确定他克莫司在中国成人肝移植受者中的群体药代动力学,并确定可能导致这种变异的因素。方法:回顾性分析262例肝移植受者的他克莫司剂量和血药浓度,以及临床资料。使用非线性混合效应建模方法分析数据。选择具有一阶吸收和消除的一室模型作为基础模型。探讨了以下参数的影响:(1)人口统计学特征;(2)生化和血液学实验室测试结果;(3)手术参数;(4)常用喜剧。结果:表观清除率(CL / F)和表观分布体积(V / F)的典型值(个体差异百分比变异系数)分别为20.9 L h -1(23.8%)和808 l(70.4%) 。剩余变异性为33.6%。最后,在这项研究中显示出与CL / F密切相关的4个协变量是日剂量,血细胞比容,总血浆蛋白和磺脲类药物的并用。磺酰脲类共疗法,较高的血细胞比容水平和升高的总蛋白可显着降低CL / F。此外,随着他克莫司日剂量的增加,CL / F呈非线性增加。结论:磺脲类药物同时治疗对他克莫司CL / F有影响。这些结果和模型将有助于临床医生优化中国肝移植患者的他克莫司治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号